<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<ns2:studies xmlns:ns2="http://webservice.caaers.cabig.nci.nih.gov">
    <ns2:study>
        <shortTitle>A Phase II Trial of Gemcitabine in Combination with 17-Allylaminogeldanamycin (17-AAG) in Advanced Epithelial Ovarian and Primary Peritoneal Carcinoma</shortTitle>
        <longTitle>A Phase II Trial of Gemcitabine in Combination with 17-Allylaminogeldanamycin (17-AAG) in Advanced Epithelial Ovarian and Primary Peritoneal Carcinoma</longTitle>
        <description>A Phase II Trial of Gemcitabine in Combination with 17-Allylaminogeldanamycin (17-AAG) in Advanced Epithelial Ovarian and Primary Peritoneal Carcinoma</description>
        <phaseCode>Phase II Trial</phaseCode>
        <status>Active - Trial is open to accrual</status>
        <multiInstitutionIndicator>true</multiInstitutionIndicator>
        <adeersReporting>true</adeersReporting>
        <otherMeddra>MedDRA v9</otherMeddra>
        <ns2:aeTerminology>
            <ns2:ctcVersion>
                <name>3</name>
            </ns2:ctcVersion>
        </ns2:aeTerminology>
        <ns2:diseaseTerminology>
            <diseaseCodeTerm>CTEP</diseaseCodeTerm>
        </ns2:diseaseTerminology>
        <drugAdministrationTherapyType>false</drugAdministrationTherapyType>
        <deviceTherapyType>false</deviceTherapyType>
        <radiationTherapyType>false</radiationTherapyType>
        <surgeryTherapyType>false</surgeryTherapyType>
        <behavioralTherapyType>false</behavioralTherapyType>
        <fundingSponsor>
            <organizationAssignedIdentifier>
                <value>6307</value>
            </organizationAssignedIdentifier>
            <ns2:studyFundingSponsor>
                <ns2:organization>
                    <name>Cancer Therapy Evaluation Program</name>
                    <nciInstituteCode>CTEP</nciInstituteCode>
                </ns2:organization>
            </ns2:studyFundingSponsor>
        </fundingSponsor>
        <coordinatingCenter>
            <organizationAssignedIdentifier>
                <value>MC0362</value>
            </organizationAssignedIdentifier>
            <ns2:studyCoordinatingCenter>
                <ns2:organization>
                    <name>Mayo Clinic Rochester</name>
                    <nciInstituteCode>MN026</nciInstituteCode>
                </ns2:organization>
            </ns2:studyCoordinatingCenter>
        </coordinatingCenter>
        <studyOrganizations>
            <ns2:studySite>
                <ns2:organization>
                    <name>Mayo Clinic Rochester</name>
                    <nciInstituteCode>MN026</nciInstituteCode>
                </ns2:organization>
                <startDate>2009-01-01</startDate>
                <endDate>2020-01-01</endDate>
            </ns2:studySite>
        </studyOrganizations>
        <identifiers/>
        <treatmentAssignments>
            <ns2:treatmentAssignment>
                <code>TAC1</code>
                <description>17-AAG:  220mg/m2 IV over 1 hr on days 1, 4, 8 and 11 q 21 days</description>
            </ns2:treatmentAssignment>
            <ns2:treatmentAssignment>
                <code>TAC2</code>
                <description>Cycle = 21 days:
Cycle 1
17-AAG:   154mg/m2 IV over 2 hrs on days 1 and 8
Gemzar:  750mg/m2 IV over 30 min on day 7
Cycle 2+
17-AAG:   154mg/m2 IV over 2 hrs on days 2 and 9
Gemzar:  750mg/m2 IV over 30 min on days 1 and 8</description>
            </ns2:treatmentAssignment>
        </treatmentAssignments>
        <studyAgents>
            <ns2:studyAgent>
                <ns2:agent>
                    <name>17-AAG</name>
                </ns2:agent>
                <indType>CTEP_IND</indType>
                <partOfLeadIND>true</partOfLeadIND>
                <studyAgentINDAssociations>
                    <ns2:studyAgentINDAssociation>
                        <ns2:investigationalNewDrug>
                            <indNumber>-111</indNumber>
                        </ns2:investigationalNewDrug>
                    </ns2:studyAgentINDAssociation>
                </studyAgentINDAssociations>
            </ns2:studyAgent>
            <ns2:studyAgent>
                <ns2:agent>
                    <name>Gemcitabine hydrochloride</name>
                </ns2:agent>
                <indType>NA_COMMERCIAL</indType>
            </ns2:studyAgent>
            <ns2:studyAgent>
                <ns2:agent>
                    <name>EPL Diluent</name>
                </ns2:agent>
                <indType>OTHER</indType>
                <partOfLeadIND>false</partOfLeadIND>
                <studyAgentINDAssociations>
                    <ns2:studyAgentINDAssociation>
                        <ns2:investigationalNewDrug>
                            <indNumber>-111</indNumber>
                        </ns2:investigationalNewDrug>
                    </ns2:studyAgentINDAssociation>
                </studyAgentINDAssociations>
            </ns2:studyAgent>
        </studyAgents>
        <ctepStudyDiseases>
            <ns2:ctepStudyDisease>
                <ns2:diseaseTerm>
                    <term>Ovarian epithelial cancer</term>
                </ns2:diseaseTerm>
                <leadDisease>true</leadDisease>
            </ns2:ctepStudyDisease>
            <ns2:ctepStudyDisease>
                <ns2:diseaseTerm>
                    <term>Primary peritoneal carcinoma</term>
                </ns2:diseaseTerm>
                <leadDisease>false</leadDisease>
            </ns2:ctepStudyDisease>
            <ns2:ctepStudyDisease>
                <ns2:diseaseTerm>
                    <term>Hematopoietic malignancy, NOS</term>
                </ns2:diseaseTerm>
                <leadDisease>false</leadDisease>
            </ns2:ctepStudyDisease>
            <ns2:ctepStudyDisease>
                <ns2:diseaseTerm>
                    <term>Solid tumor, NOS</term>
                </ns2:diseaseTerm>
                <leadDisease>false</leadDisease>
            </ns2:ctepStudyDisease>
        </ctepStudyDiseases>
        <evaluationPeriods>
            <ns2:evaluationPeriod>
                <name>Baseline</name>
                <epochOrder>0</epochOrder>
            </ns2:evaluationPeriod>
            <ns2:evaluationPeriod>
                <name>Treatment</name>
                <epochOrder>1</epochOrder>
            </ns2:evaluationPeriod>
            <ns2:evaluationPeriod>
                <name>Post-treatment</name>
                <epochOrder>2</epochOrder>
            </ns2:evaluationPeriod>
        </evaluationPeriods>
        <expectedAECtcTerms>
            <ns2:expectedAECtcTerm>
                <ctepCode>10047700</ctepCode>
            </ns2:expectedAECtcTerm>
            <ns2:expectedAECtcTerm>
                <ctepCode>10019483</ctepCode>
            </ns2:expectedAECtcTerm>
            <ns2:expectedAECtcTerm>
                <ctepCode>10003674</ctepCode>
            </ns2:expectedAECtcTerm>
            <ns2:expectedAECtcTerm>
                <ctepCode>10027787</ctepCode>
            </ns2:expectedAECtcTerm>
            <ns2:expectedAECtcTerm>
                <ctepCode>10027786</ctepCode>
            </ns2:expectedAECtcTerm>
            <ns2:expectedAECtcTerm>
                <ctepCode>10040741</ctepCode>
            </ns2:expectedAECtcTerm>
            <ns2:expectedAECtcTerm>
                <ctepCode>10016256</ctepCode>
            </ns2:expectedAECtcTerm>
            <ns2:expectedAECtcTerm>
                <ctepCode>10016558</ctepCode>
            </ns2:expectedAECtcTerm>
            <ns2:expectedAECtcTerm>
                <ctepCode>10002646</ctepCode>
            </ns2:expectedAECtcTerm>
            <ns2:expectedAECtcTerm>
                <ctepCode>10010774</ctepCode>
            </ns2:expectedAECtcTerm>
            <ns2:expectedAECtcTerm>
                <ctepCode>10012174</ctepCode>
            </ns2:expectedAECtcTerm>
            <ns2:expectedAECtcTerm>
                <ctepCode>10012727</ctepCode>
            </ns2:expectedAECtcTerm>
            <ns2:expectedAECtcTerm>
                <ctepCode>10028813</ctepCode>
            </ns2:expectedAECtcTerm>
            <ns2:expectedAECtcTerm>
                <ctepCode>10001551</ctepCode>
            </ns2:expectedAECtcTerm>
            <ns2:expectedAECtcTerm>
                <ctepCode>10003481</ctepCode>
            </ns2:expectedAECtcTerm>
            <ns2:expectedAECtcTerm>
                <ctepCode>10001675</ctepCode>
            </ns2:expectedAECtcTerm>
            <ns2:expectedAECtcTerm>
                <ctepCode>10020582</ctepCode>
            </ns2:expectedAECtcTerm>
            <ns2:expectedAECtcTerm>
                <ctepCode>10017693</ctepCode>
            </ns2:expectedAECtcTerm>
            <ns2:expectedAECtcTerm>
                <ctepCode>10020639</ctepCode>
            </ns2:expectedAECtcTerm>
            <ns2:expectedAECtcTerm>
                <ctepCode>10013573</ctepCode>
            </ns2:expectedAECtcTerm>
            <ns2:expectedAECtcTerm>
                <ctepCode>10019211</ctepCode>
            </ns2:expectedAECtcTerm>
            <ns2:expectedAECtcTerm>
                <ctepCode>10028411</ctepCode>
            </ns2:expectedAECtcTerm>
        </expectedAECtcTerms>
    </ns2:study>
</ns2:studies>
